
    
      Part A of the trial has been designed as a human safety pharmacology and therapeutic
      exploratory, parallel group, randomised, placebo-controlled, single centre, Investigator and
      subject-blind study using adaptive dose and sample size approaches.

      At the end of part A of the present study, all patients, including those receiving placebo,
      will be monitored in an open label, long-term safety follow-up part B of the study to assess
      the treatment effects over time.
    
  